#treatment

A look at fall issues from the POZ archives

The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.

POZ writers and artists have thrived at the magical intersection of lived experience and boundless talent.

A high proportion of people with HIV suffer from anxiety, which is associated with lower rates of HIV treatment and adherence to treatment.

CCR5-blocking antibody leads to long-term HIV suppression

POZ contributing writer Shawn Decker shares his journey from being a kid with no real treatment options to now.

Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.

Researchers conducted an analysis of hep C treatment outcomes in those also living with HIV in Western nations.

The increasing mastery over the virus is one of humanity’s crowning achievements.

Nearly $200 million of the pledge will go to DREAMS programs in Africa and the Caribbean.

An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.

Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.

A decade of aging brings on heart and kidney troubles in people with HIV.

A study finds that CD4 cells decline after people with HIV contract hepatitis C.